Purple Book reference family · 351(a) biologic
nogapendekin alfa inbakicept-pmln (Anktiva)
nogapendekin alfa inbakicept-pmln is an FDA-licensed reference biologic from Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc..
351(a) biologicBLA 761336 Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2024
Reference product
Originator biologic
351(a)BLA 761336
Anktiva nogapendekin alfa inbakicept-pmln
Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference nogapendekin alfa inbakicept-pmln product.
2 yr 4 mo ago
nogapendekin alfa inbakicept-pmln: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for nogapendekin alfa inbakicept-pmln.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
